The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Will The Market Value Of The Radiopharmaceutical Theranostics Market Progress Between 2026 And 2030?
The radiopharmaceutical theranostics market has shown substantial growth in recent years. It is projected to increase from $3.27 billion in 2025 to $3.76 billion in 2026, at a compound annual growth rate (CAGR) of 15.0%. The historic expansion can be linked to the wider application of nuclear medicine, rising cancer incidence rates, progress in radioisotope production techniques, increased integration of diagnostic imaging, and the initial adoption of theranostic treatment models.
The radiopharmaceutical theranostics market is poised for significant expansion over the coming years. Projections indicate it will reach $6.64 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 15.3%. This anticipated growth during the forecast period is fueled by several factors, including increasing investments in precision oncology, an escalating demand for personalized radiopharmaceutical treatments, the broadening of clinical trials for new isotopes, heightened collaboration between diagnostic and therapeutic sectors, and continuous innovation within isotope supply chains. Key trends shaping the forecast period encompass the accelerated development of targeted theranostic radiopharmaceuticals, the increasing application of PET-based personalized treatments, a greater uptake of alpha and beta emitters in cancer treatment, the expansion of cyclotron-based isotope manufacturing, and a sharpened focus on precision oncology applications.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11951&type=smp
What Factors Are Contributing To The Growth Of The Radiopharmaceutical Theranostics Market?
The rising occurrence of cancer is projected to stimulate the expansion of the radiopharmaceutical theranostics market moving forward. Cancer is defined as a complex condition marked by the abnormal multiplication of cells, which can invade and spread to other parts of the body. Radiopharmaceutical theranostics aids in cancer management by offering targeted and personalized strategies. For example, in 2023, according to the American Cancer Society, a US-based voluntary cancer health organization, an estimated 1.9 million new cancer cases are anticipated to be diagnosed in the US, with approximately 609,820 deaths potentially resulting from cancer. Furthermore, 88% of individuals diagnosed are expected to be 50 years or above. Consequently, the increasing incidence of cancer is a primary driver for the growth of the radiopharmaceutical theranostics market.
Which Segment Categories Are Included In The Radiopharmaceutical Theranostics Market Segment Analysis?
The radiopharmaceutical theranostics market covered in this report is segmented –
1) By Product Type: Alpha Emitters, Beta Emitters, Positron Emission Tomography (PET) Tracers
2) By Source: Nuclear Reactors, Cyclotrons
3) By Radioisotope: Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Other Radioscopes
4) By Indication: Oncology, Cardiology, Neurology, Other Indications
5) By End User: Hospitals, Diagnostic Imaging Centers, Academic And Research Institutes, Other End Users
Subsegments:
1) By Alpha Emitters: Actinium-225, Radium-223, Bismuth-213, Other Alpha-Emitting Radiopharmaceuticals
2) By Beta Emitters: Iodine-131, Lutetium-177, Yttrium-90, Other Beta-Emitting Radiopharmaceuticals
3) By Positron Emission Tomography (PET) Tracers: Fluorodeoxyglucose (FDG), Gallium-68, Carbon-11, Other PET Tracers
What Trends Are Shaping The Future Of The Radiopharmaceutical Theranostics Market?
Leading firms within the radiopharmaceutical theranostics market are prioritizing the creation of theranostic solutions designed to combat cancer. Furthermore, theranostic methodologies are under investigation for addressing rare diseases, striving to deliver targeted therapeutic and diagnostic options for individuals with restricted treatment avenues, including those afflicted with cancer. As an illustration, in November 2023, GE HealthCare Technologies Inc., a medical technology enterprise based in the US, introduced theranostics solutions tailored for cancer. This emerging domain of precision medicine, known as theranostics, employs therapeutic substances alongside imaging techniques to pinpoint and specifically target cancer cells for eradication.
Who Are The Active Companies Shaping The Radiopharmaceutical Theranostics Market?
Major companies operating in the radiopharmaceutical theranostics market are Cardinal Health Inc., GE HealthCare Technologies Inc., Bayer AG, China Grand Pharmaceutical & Healthcare., Lantheus Medical Imaging Inc., Curium Pharma, Advanced Accelerator Applications, Telix Pharmaceuticals Ltd., Bracco Imaging S.p.A, NTP Radioisotopes SOC Ltd., Navidea Biopharmaceuticals Inc., Jubilant DraxImage Inc., NorthStar Medical Radioisotopes LLC, Blue Earth Diagnostics Ltd., Precirix NV, SpectronRx, Viewpoint Molecular Targeting Inc., NuView Life Sciences, Alpha-9 Theranostics Inc., RadioMedix Inc, RayzeBio Inc, Fusion Pharmaceuticals Inc, Actinium Pharmaceuticals Inc., Eckert & Ziegler Strahlen- und Medizintechnik AG, Ariceum Therapeutics GmbH, Radiopharm Theranostics Ltd, Ratio Therapeutics Inc, Primo Biotechnology, Bivision Biomedical Technology (Nanjing) Co. Ltd.
Get The Full Radiopharmaceutical Theranostics Market Report:
Which Region Is The Largest In The Radiopharmaceutical Theranostics Market?
North America was the largest region in the radiopharmaceutical theranostics market in 2025. The regions covered in the radiopharmaceutical theranostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Radiopharmaceutical Theranostics Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Radiopharmaceutical Theranostics Market 2026, By The Business Research Company
Radiology As A Service Market Report 2026
https://www.thebusinessresearchcompany.com/report/radiology-as-a-service-global-market-report
Radiology Information Systems Market Report
https://www.thebusinessresearchcompany.com/report/radiology-information-systems-global-market-report
Oncologists Market Report
https://www.thebusinessresearchcompany.com/report/oncologists-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model